For decades, 7+3—consisting of cytarabine plus an anthracycline—has been the backbone of induction therapy for fit adults ...
AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...
Stocktwits on MSN
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum
The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. ・CEO Angelos ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results